Harbor-UCLA Medical Center, Torrance, CA, United States.
Harbor-UCLA Medical Center, Torrance, CA, United States.
Exp Mol Pathol. 2018 Feb;104(1):45-49. doi: 10.1016/j.yexmp.2017.12.007. Epub 2018 Jan 4.
Non-alcoholic steatohepatitis (NASH) is commonly associated with obesity, type 2 diabetes, and/or hypertriglyceridemia, while alcoholic steatohepatitis (ASH) is associated with alcohol abuse. Both NASH and ASH patients can develop cirrhosis and hepatocellular carcinoma (HCC) if left untreated. However, the rate of tumorigenesis in NASH and ASH appears to be different. Individuals with NASH progress to HCC at a rate of 0.5% annually (Lindenmeyer and McCullough, 2018), when individuals with ASH progress to HCC at a rate of 3-10% annually (Schwartz and Reinus, 2012). Thus, the objective of our study is to determine if there are differences in NASH versus ASH in the levels of different proteins expressed involved in cancer development. The method used was measuring the proteins expressed in liver biopsied sections from NASH and ASH patients using immunohistochemical staining with fluorescent antibodies and then quantitating the fluorescence intensity morphometrically. The 20 proteins tested are parts of the Ingenuity Canonical Pathway of Molecular Mechanisms of Cancer and include: RAP2B, NAIP, FYN, PAK6, SUV39H1, GNAI1, BAX, E2F3, CKDN2B, BAK1, BCL2, DIABLO, RASGRF2, GNA15, PIK3CB, BRCA1, MAP2K1, BIRC3, CDK2, and ATM. In ASH, the proteins that showed upregulated levels of expression were SUV39H1, E2F3, BCL2, BAK1, BIRC3, and GNAI1. In NASH, the proteins that showed upregulated levels of expression were BAK1 and GNAI1 and the protein that showed downregulated level of expression was BCL2. Additionally, levels of expression for SUV39H1, E2F3, BCL2, BAK1, BIRC3, and GNAI1 were significant upregulated in ASH compared to NASH. These results showed significant differences in ASH compared to normal liver, and significant differences in ASH compared to NASH. Thus, we conclude that there are more proteins involved in tumorigenesis in ASH compared to NASH and in ASH compared to normal liver, which is consistent with the known tumor development rate in ASH and NASH.
非酒精性脂肪性肝炎(NASH)通常与肥胖、2 型糖尿病和/或高甘油三酯血症有关,而酒精性脂肪性肝炎(ASH)与酗酒有关。如果不治疗,NASH 和 ASH 患者都可能发展为肝硬化和肝细胞癌(HCC)。然而,NASH 和 ASH 的肿瘤发生率似乎不同。NASH 患者每年 HCC 的发生率为 0.5%(Lindenmeyer 和 McCullough,2018 年),而 ASH 患者每年 HCC 的发生率为 3-10%(Schwartz 和 Reinus,2012 年)。因此,我们的研究目的是确定 NASH 和 ASH 在参与癌症发展的不同蛋白质水平上是否存在差异。方法是使用免疫组织化学染色用荧光抗体测量 NASH 和 ASH 患者肝活检标本中表达的蛋白质,然后用形态计量学方法定量荧光强度。测试的 20 种蛋白质是癌症的 Ingenuity 经典途径分子机制的一部分,包括:RAP2B、NAIP、FYN、PAK6、SUV39H1、GNAI1、BAX、E2F3、CKDN2B、BAK1、BCL2、DIABLO、RASGRF2、GNA15、PIK3CB、BRCA1、MAP2K1、BIRC3、CDK2 和 ATM。在 ASH 中,表达上调的蛋白质为 SUV39H1、E2F3、BCL2、BAK1、BIRC3 和 GNAI1。在 NASH 中,表达上调的蛋白质为 BAK1 和 GNAI1,表达下调的蛋白质为 BCL2。此外,与 NASH 相比,SUV39H1、E2F3、BCL2、BAK1、BIRC3 和 GNAI1 的表达水平在 ASH 中显著上调。这些结果表明,与正常肝相比,ASH 存在显著差异,与 NASH 相比,ASH 也存在显著差异。因此,我们得出结论,与 NASH 相比,ASH 中涉及肿瘤发生的蛋白质更多,与正常肝相比,ASH 中涉及肿瘤发生的蛋白质也更多,这与 ASH 和 NASH 已知的肿瘤发展速度一致。